TG Therapeutics, Inc. (TGTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, TG Therapeutics reported revenue of $616.3M, up 87.3% from $329.0M the year before. Net income was $447.2M (a 72.6% net margin), or $2.77 per diluted share. Gross margin was 83.7% and operating margin was 20.0%. Operating activities generated -$24.8M of cash, leaving -$25.0M of free cash flow. At fiscal year end, TG Therapeutics held $1.06B in total assets against $415.2M in total liabilities, including $79.1M of cash and equivalents.
Open the full interactive TG Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
TG Therapeutics Key Stats
| Share Price | $54.34 |
|---|---|
| Market Cap | $8.55B |
| P/E Ratio | 19.6 |
| Revenue YoY Growth | +87.3% |
| 52-Week Range | $26.94 – $59.06 |
| Shares Outstanding | 141.8 million (basic, 2026 Q2) |
TG Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $152,000 | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| Cost of Goods Sold | — | — | — | $14.1M | $38.5M | $100.7M |
| Gross Profit | — | — | — | $219.5M | $290.5M | $515.6M |
| Operating Income | -$273.6M | -$344.8M | -$192.8M | $20.6M | $41.9M | $123.3M |
| Pre-Tax Income | -$279.4M | -$348.1M | -$198.3M | $13.1M | $25.6M | $107.4M |
| Income Tax | $0 | $0 | $0 | $390,000 | $2.2M | -$339.8M |
| Net Income | -$279.4M | -$348.1M | -$198.3M | $12.7M | $23.4M | $447.2M |
| Diluted EPS | -$2.42 | -$2.63 | -$1.46 | $0.09 | $0.15 | $2.77 |
TG Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $161.7M | $192.6M | $204.9M | $240.3M |
| Net Income | $390.9M | $23.0M | $19.8M | $7.8M |
| Diluted EPS | $2.43 | $0.14 | $0.12 | $0.05 |
TG Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $553.4M | $298.9M | $102.3M | $92.9M | $179.9M | $79.1M |
| Current Assets | $611.7M | $331.0M | $168.3M | $317.9M | $566.4M | $630.8M |
| Total Assets | $625.6M | $379.6M | $193.6M | $329.6M | $577.7M | $1.06B |
| Current Liabilities | $87.6M | $65.4M | $53.2M | $53.7M | $90.7M | $153.8M |
| Total Long-Term Debt | $29.9M | $67.8M | $71.1M | $100.4M | $244.4M | $245.6M |
| Total Liabilities | $106.3M | $142.5M | $135.0M | $169.1M | $355.3M | $415.2M |
| Shareholders' Equity | $519.4M | $237.2M | $58.6M | $160.5M | $222.4M | $648.0M |
TG Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$214.5M | -$295.6M | -$176.2M | -$31.4M | -$40.5M | -$24.8M |
| Cash From Investing | -$24.5M | -$332,000 | -$20.0M | -$50.7M | -$1.0M | $13.8M |
| Cash From Financing | $679.8M | $41.4M | -$391,000 | $72.7M | $128.5M | -$89.7M |
| Free Cash Flow | -$214.9M | -$296.0M | -$176.2M | -$31.4M | -$40.6M | -$25.0M |
Figures from TG Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TG Therapeutics financials page for every line item.
TG Therapeutics Company Profile
| Ticker | TGTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001001316 |
Frequently Asked Questions
What was TG Therapeutics' revenue in fiscal 2025?
TG Therapeutics (TGTX) reported revenue of $616.3M for fiscal 2025.
What is TG Therapeutics' annual revenue history?
TG Therapeutics' annual revenue by fiscal year: 2020: $152,000; 2021: $6.7M; 2022: $2.8M; 2023: $233.7M; 2024: $329.0M; 2025: $616.3M.
What was TG Therapeutics' net income in fiscal 2025?
TG Therapeutics reported net income of $447.2M for fiscal 2025.
What was TG Therapeutics' earnings per share (EPS) in fiscal 2025?
TG Therapeutics' diluted EPS was $2.77 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did TG Therapeutics generate in fiscal 2025?
TG Therapeutics generated -$25.0M of free cash flow in fiscal 2025.
What was TG Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), TG Therapeutics reported revenue of $240.3M.
How much debt does TG Therapeutics have?
TG Therapeutics reported $245.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of TG Therapeutics are outstanding?
TG Therapeutics reported a weighted average of 141.8 million basic shares outstanding in 2026 Q2.
What is TG Therapeutics' market cap?
Based on its latest closing price, TG Therapeutics (TGTX) has a market capitalization of about $8.55B.
When does TG Therapeutics' fiscal year end?
TG Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is TG Therapeutics headquartered?
TG Therapeutics lists its business address in New York, New York in its SEC filings.